<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999037</url>
  </required_header>
  <id_info>
    <org_study_id>1K23DK080984-01A1</org_study_id>
    <nct_id>NCT00999037</nct_id>
  </id_info>
  <brief_title>FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease</brief_title>
  <official_title>FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      FGF-23 is a newly described protein that is an important regulator of phosphorus in the body.
      This protein increases in people with kidney disease and people who need dialysis have very
      high levels of FGF-23 in the blood. However, although some studies have indicated that FGF-23
      levels go up with increased intake of phosphorus, no one knows if FGF-23 levels can be
      lowered in patients with kidney disease by preventing them from absorbing phosphorus from
      food. This study is designed to see what happens to levels of FGF-23 in the blood when
      patients with chronic kidney disease take medications to prevent phosphorus absorption. Since
      high levels of FGF-23 have been linked with increased rates of death in patients with
      advanced kidney disease, controlling the levels may, in the future, be a way to decrease
      heart disease in patients with kidney disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FGF-23 Level</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in FGF23 value from baseline in response to Renvela at 12 weeks in comparison to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1,25(OH)2vitamin D Value</measure>
    <time_frame>12 week</time_frame>
    <description>Percentage change in 1,25(OH)2vitamin D level from baseline at 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Phosphate Concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in serum phosphate at 12 weeks from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Renvela</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily renvela with meals for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer Carbonate</intervention_name>
    <description>Daily renvela (800 mg tid with meals) x 12 weeks</description>
    <arm_group_label>Renvela</arm_group_label>
    <other_name>Renvela</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 inert tablet tid x 12 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria include pediatric patients, between the ages of 2 and 21 years,
             with CKD stages 2-4 (GFR 15-90 ml/min/1.73m2).

        Exclusion Criteria:

          -  Exclusion criteria include: the use of phosphate binder therapy within the past 3
             months, treatment with 25(OH)vitamin D or 1,25dihydroxyvitamin D, underlying metabolic
             bone disease, or underlying renal phosphate wasting disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2009</study_first_submitted>
  <study_first_submitted_qc>October 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2009</study_first_posted>
  <results_first_submitted>December 22, 2016</results_first_submitted>
  <results_first_submitted_qc>February 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 31, 2017</results_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Katherine Wesseling-Perry</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Renvela</title>
          <description>Sevelamer Carbonate (Renvela) 800 mg tablets: 1 tablet TID with meals for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (inert tablets): 1 tablet TID with meals for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9">20</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Renvela</title>
          <description>Daily renvela with meals for 12 weeks
Sevelamer Carbonate: Daily renvela (800 mg tid with meals) x 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: 1 inert tablet tid x 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.3" spread="3.2"/>
                    <measurement group_id="B2" value="15.4" spread="4.6"/>
                    <measurement group_id="B3" value="14.3" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in FGF-23 Level</title>
        <description>Change in FGF23 value from baseline in response to Renvela at 12 weeks in comparison to placebo.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renvela</title>
            <description>Sevelamer Carbonate (800 mg tablet) PO TID with meals x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (1 inert tablet) PO TID with meals x 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FGF-23 Level</title>
          <description>Change in FGF23 value from baseline in response to Renvela at 12 weeks in comparison to placebo.</description>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="41"/>
                    <measurement group_id="O2" value="41" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1,25(OH)2vitamin D Value</title>
        <description>Percentage change in 1,25(OH)2vitamin D level from baseline at 12 weeks.</description>
        <time_frame>12 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renvela</title>
            <description>Daily renvela with meals for 12 weeks
Sevelamer Carbonate: Daily renvela (800 mg tid with meals) x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 1 inert tablet tid x 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>1,25(OH)2vitamin D Value</title>
          <description>Percentage change in 1,25(OH)2vitamin D level from baseline at 12 weeks.</description>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" spread="64"/>
                    <measurement group_id="O2" value="69" spread="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Phosphate Concentration</title>
        <description>Change in serum phosphate at 12 weeks from baseline</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renvela</title>
            <description>Daily renvela with meals for 12 weeks
Sevelamer Carbonate: Daily renvela (800 mg tid with meals) x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 1 inert tablet tid x 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Phosphate Concentration</title>
          <description>Change in serum phosphate at 12 weeks from baseline</description>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" spread="46"/>
                    <measurement group_id="O2" value="-8" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Renvela</title>
          <description>Daily renvela with meals for 12 weeks
Sevelamer Carbonate: Daily renvela (800 mg tid with meals) x 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: 1 inert tablet tid x 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Katherine Wesseling-Perry</name_or_title>
      <organization>University of California at Los Angeles</organization>
      <phone>310-206-6987</phone>
      <email>kwesseling@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

